A federal deadline ending sale of off-brand weight-loss and diabetes medications is now in effect, cutting off access to ...

The patent on weight loss injection semaglutide is due to expire in 2031, which will let other companies make cut-price ...

Excess body weight can raise the risk of certain cancers, leading researchers to wonder whether blockbuster drugs like Wegovy ...

KATIE Price has sparked concern after she looked slimmer than ever in her latest Instagram post. The star, 47, has been ...

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to ...

Eli Lilly plans to pursue approval for its new GLP-1 pill by the end of this year. Fact checked by Nick Blackmer A daily pill ...

Alzheimer's disease costs the global economy $1.3trillion a year. That is the estimate from the Alzheimer's Society.

Despite early success, however, Novo Nordisk has fallen behind in the GLP-1RA race, overtaken by Eli Lilly and its GLP-1RA ...

Providers of compounded obesity drugs are finding—for now—a new way into the booming market by tweaking formulations.

The boss of Ozempic maker Novo Nordisk lost his job yesterday after its share price plunged amid intensifying competition in the multi-billion pound fat jab market. Lars Fruergaard Jorgensen is being ...

Zealand Pharma A/S' obesity drug pipeline, including petrelintide, shows promise but faces high risks. Click to explore ZLDPF ...

FRANKFURT, Germany (AP) — Danish pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy, said ...